BioTuesdays
3D Signatures

3DS makes final patent payment

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) recently made the final payment to CancerCare Manitoba (CCMB) for the purchase of intellectual property. All patents were assigned from CCMB to 3DS in June 2014. Quarterly...

Jaguar Animal Health

Jaguar seeks MUMS designation for EID in dogs

Jaguar Animal Health (NASDAQ:JAGX) has submitted a formal request to the FDA’s Center for Veterinary Medicine for a determination whether Canalevia qualifies under the requirements of the Minor Use and Minor Species...

BioTime

BioTime opens U.S. sites in dry AMD trial

BioTime (NYSE MKT:BTX) is expanding its ongoing Phase 1/2a clinical trial for OpRegen in the advanced dry form of AMD by naming the first two sites that will treat patients in the U.S. “The addition of U.S. clinical...

Histogenics

Histogenics cartilage data published

Histogenics (NASDAQ:HSGX) announced the online peer-reviewed publication in the Journal of Orthopaedic Research that analyzes mechanical properties of tissue engineered cartilage based on work done as part of a...

BioLight Life Sciences Ltd.

BioLight TeaRx to be used in DES trial

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) announced that one of its subsidiaries, DiagnosTear, has signed a services agreement with a pharmaceuticals company to provide analysis services with its TeaRx multi...

3D Signatures

3DS initiates HL validation program

The validation program for 3D Signatures’ (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) Hodgkin’s lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company’s TeloView software platform. The purpose of Telo...

Arch Therapeutics

Arch in $6.1-million registered direct offering

Arch Therapeutics (OTCQB:ARTH) priced a registered direct offering of 10,166,664 units, with each unit consisting of a common share and 0.55 of a Series F warrant, at a purchase price of 60 cents a unit for gross...

Soricimed Logo

Soricimed publishes Phase 1 results of SOR-C13

Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium...

Arch Therapeutics

Arch advances 510(k) filing for AC5 hemostat

Arch Therapeutics (OTCQB:ARTH) announced that the 510(k) filing for external use of the AC5 Topical Hemostatic device would be advanced to mid-2017 from the previously announced target of late 2017. “Our...

microbix

Microbix posts 84% jump in Q1 revenue

Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier. Strong growth in Asian markets and increased sales to the...

The Massachusetts Life Sciences Center

Mass. Life Sciences launches ramp-up program

The Massachusetts Life Sciences Center (MLSC) has launched the Massachusetts Ramp-Up Program (MassRamp), a new program that will provide grant funding to promising early-stage life sciences companies. The program will...